Premium
T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia
Author(s) -
Westermann Jörg,
Schlimper Claudia,
Richter Günther,
Mohm Johannes,
Dörken Bernd,
Pezzutto Antonio
Publication year - 2004
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.04873.x
Subject(s) - breakpoint cluster region , immunology , medicine , myeloid , t cell , peripheral blood mononuclear cell , antibody , hematology , immune system , cancer research , biology , receptor , in vitro , biochemistry
Summary In chronic myeloid leukaemia (CML), peptides from the fusion region of bcr3/abl2 are likely to play a role in anti‐leukaemic T cell immunity. We investigated whether T cells that recognize bcr/abl fusion peptides could be detected in healthy donors and CML patients. T cell responses against bcr3/abl2 fusion peptides were analysed by γ ‐interferon enzyme‐linked immunospot assays after prestimulation of peripheral blood mononuclear cells in the presence of anti‐CD3‐antibodies and interleukin‐2. Our results suggest that the T cell repertoire contains bcr3/abl2‐reactive T cells in CML patients who are in cytogenetic remission, but also in some healthy individuals.